Loading...
•
Dec 31, 2021
Vericel Q4 2021 Earnings Report
Vericel reported financial results for Q4 and full year 2021 and provided full-year 2022 financial guidance.
Key Takeaways
Vericel reported a 5% increase in total net revenue for the fourth quarter of 2021, reaching $47.6 million. Net income was $4.5 million, or $0.09 per share, and non-GAAP adjusted EBITDA was $12.8 million.
Total net revenue of $47.6 million, compared to $45.2 million in the fourth quarter of 2020.
MACI® net revenue of $37.3 million, Epicel® net revenue of $9.7 million, and NexoBrid® revenue of $0.5 million related to the U.S. Biomedical Advanced Research and Development Authority (BARDA) procurement for emergency response preparedness
Net income of $4.5 million, or $0.09 per share, compared to $12.2 million, or $0.25 per share, in the fourth quarter of 2020.
Non-GAAP adjusted EBITDA of $12.8 million, compared to $16.0 million in the fourth quarter of 2020.
Vericel
Vericel
Vericel Revenue by Segment
Revenue by Segment
MACI Net Revenue
CapyFin.comEpicel Net Revenue
CapyFin.comNexoBrid Net Revenue
CapyFin.com Forward Guidance
Total net revenue for 2022 expected to be in the range of $178 to $189 million. MACI revenue expected to be in the range of $132 to $141 million. Epicel revenue expected to be in the range of $45.5 to $47.5 million. Gross margin expected to be approximately 70%. Adjusted EBITDA margin expected to be approximately 21%.
Positive Outlook
- Total net revenue for 2022 expected to be in the range of $178 to $189 million.
- MACI revenue expected to be in the range of $132 to $141 million.
- Epicel revenue expected to be in the range of $45.5 to $47.5 million.
- Gross margin expected to be approximately 70%.
- Adjusted EBITDA margin expected to be approximately 21%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income